{"id":449,"date":"2026-08-27T10:31:11","date_gmt":"2026-08-27T10:31:11","guid":{"rendered":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/"},"modified":"2026-08-28T07:42:46","modified_gmt":"2026-08-28T07:42:46","slug":"retatrutide-triple-agonist-phase-2-evidence","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/fr\/retatrutide-triple-agonist-phase-2-evidence\/","title":{"rendered":"Triple agonisme Retatrutide\u00a0: ce que l'essai de phase 2 a d\u00e9couvert et n'a pas prouv\u00e9"},"content":{"rendered":"
Retatrutide est con\u00e7u pour activer les r\u00e9cepteurs GIP, GLP-1 et le glucagon dans une seule mol\u00e9cule. Son essai de phase 2023 sur l'ob\u00e9sit\u00e9 2 a suscit\u00e9 un int\u00e9r\u00eat consid\u00e9rable, mais l'interpr\u00e9tation correcte d\u00e9pend de la phase de l'essai, de la population, des crit\u00e8res d'\u00e9valuation, des r\u00e9sultats des \u00e9v\u00e9nements ind\u00e9sirables et de ce qui reste inconnu.<\/p>
Points cl\u00e9s \u00e0 retenir<\/h2>
Retatrutide est une mol\u00e9cule exp\u00e9rimentale unique ayant une activit\u00e9 sur trois r\u00e9cepteurs hormonaux.<\/li>
Les r\u00e9sultats fr\u00e9quemment cit\u00e9s proviennent d\u2019un essai de phase 2 avec des participants 338, et non d\u2019une d\u00e9cision d\u2019approbation.<\/li>
L\u2019ach\u00e8vement de l\u2019\u00e9tude de phase 3 ne signifie pas en soi que les r\u00e9sultats sont publi\u00e9s ou qu\u2019un produit est approuv\u00e9.<\/li><\/ul><\/div><\/div>Illustration \u00e9ditoriale originale de trois voies de signalisation des r\u00e9cepteurs dans un laboratoire de recherche\u00a0; pas une repr\u00e9sentation de l\u2019administration clinique.<\/figcaption><\/figure>
Le concept \u00e0 trois r\u00e9cepteurs<\/h2>
Retatrutide, \u00e9galement identifi\u00e9 dans les dossiers de d\u00e9veloppement sous le nom de LY3437943, est un agoniste des r\u00e9cepteurs GIP, GLP-1 et du glucagon. Le qualifier de triple agoniste d\u00e9crit la pharmacologie des r\u00e9cepteurs\u00a0; il ne permet pas en soi de pr\u00e9dire l\u2019ampleur, la durabilit\u00e9 ou la s\u00e9curit\u00e9 d\u2019un r\u00e9sultat dans une population particuli\u00e8re.<\/p>
L\u2019\u00e9quilibre d\u2019activit\u00e9 entre les trois r\u00e9cepteurs, le profil d\u2019exposition de la mol\u00e9cule et la formulation \u00e9tudi\u00e9e contribuent tous aux effets observ\u00e9s.<\/p>
Ce que l'\u00e9tude de phase 2 a mesur\u00e9<\/h2>
L'essai randomis\u00e9, en double aveugle et contr\u00f4l\u00e9 par placebo a recrut\u00e9 338 adultes souffrant d'ob\u00e9sit\u00e9 ou de surpoids et d'une maladie li\u00e9e au poids. Le crit\u00e8re d'\u00e9valuation principal \u00e9tait le pourcentage de variation du poids corporel \u00e0 24 semaines\u00a0; Le changement sur 48 semaines et les seuils cat\u00e9goriels de r\u00e9duction de poids \u00e9taient des crit\u00e8res d'\u00e9valuation secondaires. Les \u00e9v\u00e9nements gastro-intestinaux \u00e9taient les \u00e9v\u00e9nements ind\u00e9sirables les plus courants, et des augmentations de la fr\u00e9quence cardiaque d\u00e9pendantes de la dose ont \u00e9t\u00e9 observ\u00e9es avant de diminuer plus tard au cours de l'\u00e9tude.<\/p>
L\u2019\u00e9tude a \u00e9tabli un signal dose-r\u00e9ponse et a soutenu le d\u00e9veloppement de la phase 3. Elle n\u2019a pas \u00e9tabli le rapport b\u00e9n\u00e9fice-risque \u00e0 long terme sur des populations plus larges, la sup\u00e9riorit\u00e9 directe sur toutes les alternatives ou l\u2019\u00e9quivalence entre le mat\u00e9riel d\u2019essai et un produit catalogue.<\/p>
Conception<\/strong>Essai de phase 2 randomis\u00e9, en double aveugle et contr\u00f4l\u00e9 par placebo<\/span><\/div>
Participants<\/strong>338 adultes<\/span><\/div>
Dur\u00e9e<\/strong>Semaines 48<\/span><\/div>
Limite cl\u00e9<\/strong>Preuve d'enqu\u00eate, pas une approbation FDA<\/span><\/div><\/div><\/div>
Ce qui a chang\u00e9 par 2026<\/h2>
ClinicalTrials.gov r\u00e9pertorie TRIUMPH-1 comme une \u00e9tude de phase 3 termin\u00e9e, avec un ach\u00e8vement de l'\u00e9tude en avril 2026 et aucun r\u00e9sultat publi\u00e9 dans le dossier examin\u00e9 pour cet article. \u00ab\u00a0Termin\u00e9\u00a0\u00bb d\u00e9crit le statut de l'\u00e9tude\u00a0; il ne remplace pas les r\u00e9sultats, l\u2019examen par les pairs ou l\u2019\u00e9valuation r\u00e9glementaire.<\/p>
Les informations publiques actuelles de FDA indiquent que le r\u00e9tatrutide n\u2019est pas un composant d\u2019un m\u00e9dicament approuv\u00e9 par FDA. Un article 2026 pr\u00e9cis devrait donc le d\u00e9crire comme exp\u00e9rimental, \u00e0 moins et jusqu'\u00e0 ce qu'un dossier d'approbation faisant autorit\u00e9 indique le contraire.<\/p>
Phase sup\u00e9rieure de 3 rapport\u00e9e par le sponsor 2026<\/h2>
Lilly a rapport\u00e9 les premiers r\u00e9sultats pour TRIUMPH-1 en mai 21, 2026\u00a0: au cours des semaines 80, le sponsor a signal\u00e9 un changement de poids moyen de \u221228.3% pour le groupe 12 mg. En juillet 23, 2026, Lilly a signal\u00e9 des changements moyens allant jusqu'\u00e0 \u221220.8% dans TRIUMPH-2 et \u221222.6% dans TRIUMPH-3. Il s\u2019agit de divulgations du sponsor principal, et non de modules de r\u00e9sultats de ClinicalTrials.gov ou de rapports complets \u00e9valu\u00e9s par des pairs\u00a0; les m\u00e9thodes d\u00e9taill\u00e9es, les d\u00e9cisions d\u2019analyse et les tableaux complets des \u00e9v\u00e9nements ind\u00e9sirables n\u00e9cessitent toujours les \u00e9ventuels enregistrements complets. ClinicalTrials.gov a continu\u00e9 \u00e0 afficher \u00ab\u00a0Aucun r\u00e9sultat publi\u00e9\u00a0\u00bb pour TRIUMPH-1 lors de cette revue.<\/p>","protected":false},"excerpt":{"rendered":"
Une lecture attentive de la pharmacologie des r\u00e9cepteurs GIP, GLP-1 et du glucagon du r\u00e9tatrutide et de l'essai sur l'ob\u00e9sit\u00e9 2 de phase d'une semaine 48, y compris les limites et l'\u00e9tat actuel de l'enqu\u00eate.<\/p>","protected":false},"author":1,"featured_media":619,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pim_family_ids":"359","pim_article_type":"Clinical trial evidence review","pim_evidence_level":"Randomized phase 2 human trial; investigational status","pim_reviewer":"NHD evidence editorial workflow","pim_reviewed_date":"2026-08-28","pim_editorial_note":"Source-checked against the linked primary or authoritative records on 2026-08-27. This is an evidence summary, not independent peer review, medical advice or validation of a catalog lot.","pim_review_status":"reviewed","pim_review_reason":"At least two linked primary or authoritative records and an explicit evidence boundary are present.","pim_creation_method":"The editorial workflow starts with linked peer-reviewed papers, trial registries or regulatory records; extracts the population or model, endpoints, numerical results and limitations; and separates the studied intervention from catalog material. AI-assisted drafting was used to structure the first version. Claims, figures, evidence labels and limitations were checked against the linked records in the site editorial workflow. This is not independent peer review.","pim_sources":"[{\"title\":\"Triple-Hormone-Receptor Agonist Retatrutide for Obesity \u2014 phase 2 trial\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37366315\/\",\"note\":\"Primary randomized phase 2 record; PMID 37366315.\"},{\"title\":\"TRIUMPH-1 phase 3 study record\",\"url\":\"https:\/\/clinicaltrials.gov\/study\/NCT05929066\",\"note\":\"ClinicalTrials.gov record updated June 2026; results not posted in the reviewed record.\"},{\"title\":\"FDA information on unapproved GLP-1 products\",\"url\":\"https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss\",\"note\":\"Current regulatory-status boundary.\"},{\"title\":\"TRIUMPH-1 sponsor-reported topline results\",\"url\":\"https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss\",\"note\":\"Lilly primary-sponsor news release, May 21, 2026; not a peer-reviewed full report.\"},{\"title\":\"TRIUMPH-2 and TRIUMPH-3 sponsor-reported topline results\",\"url\":\"https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-triple-agonist-retatrutide-successful-two-additional\",\"note\":\"Lilly primary-sponsor news release, July 23, 2026; detailed results remain pending.\"}]","footnotes":""},"categories":[18],"tags":[],"class_list":["post-449","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-evidence-reviews"],"yoast_head":"\n
Retatrutide Triple Agonism: What the Phase 2 Trial Found\u2014and Did Not Prove - NHD<\/title>\n<meta name=\"description\" content=\"A close reading of retatrutide\u2019s GIP, GLP-1 and glucagon receptor pharmacology and the 48-week phase 2 obesity trial, including limitations and current investigational status.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/fr\/retatrutide-triple-agonist-phase-2-evidence\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Retatrutide Triple Agonism: What the Phase 2 Trial Found\u2014and Did Not Prove\" \/>\n<meta property=\"og:description\" content=\"A close reading of retatrutide\u2019s GIP, GLP-1 and glucagon receptor pharmacology and the 48-week phase 2 obesity trial, including limitations and current investigational status.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/fr\/retatrutide-triple-agonist-phase-2-evidence\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-27T10:31:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-28T07:42:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/retatrutide-triple-agonist-phase-2-evidence-featured-v2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"960\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NHD Technical Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"NHD Technical Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/\"},\"author\":{\"name\":\"NHD Technical Team\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\"},\"headline\":\"Retatrutide Triple Agonism: What the Phase 2 Trial Found\u2014and Did Not Prove\",\"datePublished\":\"2026-08-27T10:31:11+00:00\",\"dateModified\":\"2026-08-28T07:42:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/\"},\"wordCount\":444,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/retatrutide-triple-agonist-phase-2-evidence-featured-v2.webp\",\"articleSection\":[\"Evidence Reviews\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/\",\"name\":\"Retatrutide Triple Agonism: What the Phase 2 Trial Found\u2014and Did Not Prove - NHD\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/retatrutide-triple-agonist-phase-2-evidence-featured-v2.webp\",\"datePublished\":\"2026-08-27T10:31:11+00:00\",\"dateModified\":\"2026-08-28T07:42:46+00:00\",\"description\":\"A close reading of retatrutide\u2019s GIP, GLP-1 and glucagon receptor pharmacology and the 48-week phase 2 obesity trial, including limitations and current investigational status.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/retatrutide-triple-agonist-phase-2-evidence-featured-v2.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/retatrutide-triple-agonist-phase-2-evidence-featured-v2.webp\",\"width\":1536,\"height\":960,\"caption\":\"Article-specific editorial image.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Retatrutide Triple Agonism: What the Phase 2 Trial Found\u2014and Did Not Prove\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\",\"name\":\"NHD Technical Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"caption\":\"NHD Technical Team\"},\"description\":\"NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.\",\"sameAs\":[\"https:\\\/\\\/nhdbio.com\"],\"url\":\"https:\\\/\\\/nhdbio.com\\\/fr\\\/author\\\/qianmiao-technical-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Triple agonisme Retatrutide\u00a0: ce que l'essai de phase 2 a d\u00e9couvert et n'a pas prouv\u00e9 - NHD","description":"Une lecture attentive de la pharmacologie des r\u00e9cepteurs GIP, GLP-1 et du glucagon du r\u00e9tatrutide et de l'essai sur l'ob\u00e9sit\u00e9 2 de phase d'une semaine 48, y compris les limites et l'\u00e9tat actuel de l'enqu\u00eate.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/fr\/retatrutide-triple-agonist-phase-2-evidence\/","og_locale":"fr_FR","og_type":"article","og_title":"Retatrutide Triple Agonism: What the Phase 2 Trial Found\u2014and Did Not Prove","og_description":"A close reading of retatrutide\u2019s GIP, GLP-1 and glucagon receptor pharmacology and the 48-week phase 2 obesity trial, including limitations and current investigational status.","og_url":"https:\/\/nhdbio.com\/fr\/retatrutide-triple-agonist-phase-2-evidence\/","og_site_name":"NHD","article_published_time":"2026-08-27T10:31:11+00:00","article_modified_time":"2026-08-28T07:42:46+00:00","og_image":[{"width":1536,"height":960,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/retatrutide-triple-agonist-phase-2-evidence-featured-v2.webp","type":"image\/webp"}],"author":"NHD Technical Team","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"\u00c9crit par":"NHD Technical Team","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/#article","isPartOf":{"@id":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/"},"author":{"name":"NHD Technical Team","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1"},"headline":"Retatrutide Triple Agonism: What the Phase 2 Trial Found\u2014and Did Not Prove","datePublished":"2026-08-27T10:31:11+00:00","dateModified":"2026-08-28T07:42:46+00:00","mainEntityOfPage":{"@id":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/"},"wordCount":444,"commentCount":0,"publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"image":{"@id":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/retatrutide-triple-agonist-phase-2-evidence-featured-v2.webp","articleSection":["Evidence Reviews"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/","url":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/","name":"Triple agonisme Retatrutide\u00a0: ce que l'essai de phase 2 a d\u00e9couvert et n'a pas prouv\u00e9 - NHD","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/retatrutide-triple-agonist-phase-2-evidence-featured-v2.webp","datePublished":"2026-08-27T10:31:11+00:00","dateModified":"2026-08-28T07:42:46+00:00","description":"Une lecture attentive de la pharmacologie des r\u00e9cepteurs GIP, GLP-1 et du glucagon du r\u00e9tatrutide et de l'essai sur l'ob\u00e9sit\u00e9 2 de phase d'une semaine 48, y compris les limites et l'\u00e9tat actuel de l'enqu\u00eate.","breadcrumb":{"@id":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/retatrutide-triple-agonist-phase-2-evidence-featured-v2.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/retatrutide-triple-agonist-phase-2-evidence-featured-v2.webp","width":1536,"height":960,"caption":"Article-specific editorial image."},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"Retatrutide Triple Agonism: What the Phase 2 Trial Found\u2014and Did Not Prove"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Mati\u00e8res premi\u00e8res peptidiques et synth\u00e8se sur mesure","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1","name":"\u00c9quipe technique NHD","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","caption":"NHD Technical Team"},"description":"L'\u00e9quipe technique NHD maintient la documentation du catalogue d'utilisation de la recherche et les r\u00e9sum\u00e9s des preuves. Les articles examin\u00e9s renvoient \u00e0 des articles \u00e9valu\u00e9s par des pairs, \u00e0 des registres d'essais et \u00e0 des dossiers r\u00e9glementaires, conservent les r\u00e9sultats nuls et les limites des \u00e9tudes, et distinguent les interventions publi\u00e9es des documents du catalogue. Le dessin assist\u00e9 par AI peut \u00eatre utilis\u00e9 pour la structure\u00a0; les liens vers les sources et les limites des preuves restent visibles. Ce travail ne constitue pas un examen ind\u00e9pendant par des pairs ni un avis m\u00e9dical.","sameAs":["https:\/\/nhdbio.com"],"url":"https:\/\/nhdbio.com\/fr\/author\/qianmiao-technical-team\/"}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts\/449","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/comments?post=449"}],"version-history":[{"count":2,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts\/449\/revisions"}],"predecessor-version":[{"id":528,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts\/449\/revisions\/528"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/media\/619"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/media?parent=449"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/categories?post=449"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/tags?post=449"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![\"Chercheur](\"http:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/metabolic-peptide-receptor-research.png\")